Nexentis Technologies filed a prospectus for an offering of 2.573M common shares on behalf of selling shareholders. The filing was submitted to the Securities and Exchange Commission (SEC) and outlines the details of the proposed sale.

Offering Details

The prospectus covers the sale of common shares, with the total number of shares listed at 2.573M. The offering is being conducted on behalf of selling shareholders, meaning the proceeds will go to the shareholders rather than the company.

Regulatory Filing

document was filed with the SEC, providing necessary disclosures for the offering. The prospectus includes information about the shares being offered and the terms of the sale.

MitoCareX Bio, a wholly owned subsidiary of Nexentis Technologies, has completed a broad analysis of SLC transport proteins and entered an international AI drug discovery initiative with Boltz, PBC, to accelerate the discovery of novel small-molecule modulators for hard-to-treat cancers and inflammatory metabolic diseases. The initiative aims to enhance the efficiency of identifying and progressing drug candidates by combining MitoCareX Bio's proprietary MITOLINE algorithm with Boltz's biomolecular foundation models.

SLC Analysis Achievement

MitoCareX Bio's analysis builds on its MITOLINE sequence analysis and alignment algorithm, which has been used to prepare mitochondrial SLC carrier proteins for structural modeling in drug discovery. The new analysis identified additional SLC proteins outside the mitochondrial SLC25 family that appear compatible with the MITOLINE ruleset, suggesting these transporters may also be amenable to MITOLINE-enabled structural modeling. This step aligns with MitoCareX Bio's strategy to expand its small-molecule discovery capabilities into additional disease-relevant transport proteins.

AI Initiative with Boltz

Boltz, an AI research lab focusing on biomolecular foundation models and drug discovery workflows, brings its BoltzMol-1 small-molecule generative pipeline to the partnership. This pipeline is designed to model complex structures and binding affinities, supporting in silico screening and design of small molecules. MitoCareX Bio intends to integrate its MITOLINE platform with Boltz's foundation models to predict biomolecular structure and binding affinity, leveraging two complementary and independently validated capabilities.

Strategic Context

Nexentis Technologies is positioning MitoCareX Bio as a drug discovery company focusing on SLC transporters in oncology and metabolic disease indications. The completion of the SLC analysis and the launch of the AI initiative with Boltz are part of Nexentis' roadmap to advance MitoCareX Bio's discovery capabilities and expand its pipeline of SLC-focused small-molecule programs. Boltz has publicly highlighted its collaborations with industry partners, including Pfizer and Takeda, underscoring the potential of its AI-driven approach.